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A B S T R A C T
Ttranscatheter aortic valve implantation (TAVI) is currently reserved for high surgical 
risk or inoperable patients. There are currently two types of valves being implanted, 
the Medtronic Corevalve and the Edwards SAPIEN device. In 2007, TAVI actually 
represented approximately 1.2% of all aortic valve procedures in Europe; this per-
centage increased to 6.5% in 2008. With an expectation of ~9000 TAVI procedures 
to be performed in 2009, TAVI may represent nearly 13% of all aortic valve proce-
dures. It is forecasted that by 2012 transcatheter valve therapies will account for ap-
proximately 40% of the total heart valve procedures performed in Europe. One major 
limiting factor relates to procedural complications of TAVI. Conduction abnormali-
ties and the need for permanent pacemaker, paravalvular aortic regurgitation, stroke 
and vascular complications have received particular attention. After implantation of 
the CoreValve device, the need for new permanent pacemaker has been reported to 
be in the range of 19–35%. In contrast, approximately 4–7% of patients are in need 
of permanent pacemaker after implantation of the Edwards device. The future and 
widespread adoption of TAVI will rely on a number of inter-related factors, including 
long-term durability and safety data, randomized controlled trials comparing TAVI 
with surgical aortic valve replacement and reimbursement for the technology.
I N T R O D U C T I O N
It is forecasted that by 2012 transcatheter valve (TCV) therapies will account for 
approximately 40% of the total heart valve procedures performed in Europe (Fig. 
1).1,2 The absolute number of surgical valve procedures, however, is projected to rise 
during this period. Thus, TCV therapies will expand the total pool of treatable patients 
with heart valve disease. Although transcatheter aortic valve implantation (TAVI) has 
become recognized as a viable alternative for high-risk or inoperable patients, many 
important questions remain unanswered. The goal of this opinion piece is to highlight 
areas where further research and advancement is needed in this burgeoning field. More 
specifically, we will address issues related to patient selection and risk scores, procedural 
complications, and standardization of the definition of clinical endpoints.
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P A T I E N T  S E L E C T I O N  A N D  S U R G I C A L 
R I S K  S C O R E S
TAVI is currently reserved for high surgical risk or inoper-
able patients. Surgical risk scores (SRS), such as the Society of 
Thoracic Surgeons (STS) predicted risk of mortality (PROM) 
and logistic EuroSCORE, are used commonly to identify such 
patients for clinical trials.3,4 Furthermore, these SRS are used 
as benchmark performance measures for TAVI procedures. 
The application of SRS for transcatheter procedures can be 
associated with significant limitations. Firstly, it is important 
to appreciate the surgical population that was used to develop 
the risk score. For example, the logistic EuroSCORE was 
based on a general cardiac surgery population whereby 60% 
of patients had coronary artery bypass surgery, 30% had valve 
surgery and 10% had other cardiac-related surgeries. On the 
other hand, the STS risk score was based on patients under-
going valve surgery. Furthermore, ‘inoperable patients’ were 
obviously excluded during model development and high-risk 
patients likely accounted for a minority of those included in 
the analysis.
Although not particular to the STS or logistic Euro-
SCORE, several measurable and unmeasurable risk factors 
known to influence mortality are not factored into the equa-
tion.5,6 For example, both models fail to include porcelain aorta 
and, more importantly, the frailty of the patient.7 Also, using 
these surgical risk scores as benchmark performance measures 
for an unrelated procedure, such as TAVI, is not scientifically 
sound. This can lead to complacency on the part of the treat-
ing physician, especially when the surgical risk score grossly 
overestimates the actual mortality risk of the TAVI procedure. 
In summary, two risk scores would be needed8:
A surgical risk score (developed using surgical patients) 
to help identify high-risk patients.
A transcatheter risk score (developed using transcatheter 
patients) to act as a performance measure and improve 
patient-informed consent.
Risk scores for these purposes are lacking currently and 
should be the focus of future studies.
P R O C E D U R A L  C O M P L I C A T I O N S
The acute efficacy results are fostering the necessary 
enthusiasm and support for further development of the tech-
nology. What is perhaps of greater interest and importance is 
to understand the mechanisms behind the complications, to 
develop treatment strategies that either mitigate or prevent 
the complications and, finally, to appreciate the acute and 
long-term clinical implications of the complications. Conduc-
tion abnormalities and the need for permanent pacemaker, 
paravalvular aortic regurgitation, stroke and vascular compli-
cations have received particular attention and will be further 
discussed below.
C O N D U C T I O N  A B N O R M A L I T I E S  A N D 
P E R M A N E N T  P A C E M A K E R  R E Q U I R E M E N T
New-onset left bundle branch block (LBBB) has been re-
ported in up to 40% of patients implanted with the CoreValve 
device (Medtronic, Inc, Minneapolis, MN) and in 7% of pa-
tients implanted with the Edwards SAPIEN device (Edwards 
Lifesciences, Irvine, California).9-11 Paralleling these figures is 
the need for permanent pacemaker implantation.
After implantation of the CoreValve device, the need for 
new permanent pacemaker has been reported to be in the 
range of 19–35% (Fig. 2A).9,10,12-15 In contrast, approximately 
4–7% of patients are in need of permanent pacemaker after 
implantation of the Edwards device (Fig. 2B).16-19 It must be 
highlighted that some centers implant permanent pacemakers 
on a ‘prophylactic’ basis (e.g. new-onset LBBB or asympto-
matic bradycardia) or for administrative logistical purposes 
(e.g. promote earlier discharge). This may partly explain the 
wide range of observed permanent pacemaker implantation 
rates.
We have previously shown that the depth of implantation 
of the CoreValve device is associated with the development 
of LBBB (10.3 mm in those patients with new-onset LBBB 
vs. 5.3 mm in those without).9 Thus, we hypothesize that a 
more superior positioning of the CoreValve device within 
the left ventricular outflow tract may mitigate conduction 
abnormalities and reduce the need for permanent pacemaker. 
To put this into perspective, the Edwards SAPIEN device is 
implanted approximately 4–6 mm below the aortic valve an-
nulus (basal attachment point of aortic valve leaflets), whereas 
the CoreValve, in our experience, is implanted a mean of 
•
•
FIGURE 1. Percentage of total heart valve procedures expected 
to rise substantially from 2007– 2012.
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9-10 mm below the aortic valve annulus. It is currently being 
recommended to position the CoreValve device approximately 
6 mm below the aortic annulus.
P A R A V A L V U L A R  A O R T I C  R E G U R G I T A T I O N
Moderate-to-severe paravalvular aortic regurgitation is 
poorly tolerated after TAVI. In these cases, patients typi-
cally experience recurrent heart failure and longer lengths of 
stay in the intensive care units. According to the Expanded 
Evaluation Registry with the CoreValve device (n=1378) 
and the SOURCE registry with the Edwards SAPIEN device 
(n=1308), grade 3 or grade 4 paravalvular aortic regurgitation 
was observed in 3% and 5% of patients, respectively.17,20 Of 
the remaining patients, approximately one-fifth had grade 0 
paravalvular aortic regurgitation, two-thirds had grade 1 and 
one-fifth had grade 2. Anecdotal experience suggests that 
patients with grade 1 or 2 aortic regurgitation have a benign 
clinical course but this observation needs to be confirmed in 
larger clinical studies. The pericardial skirt of the Edwards 
and CoreValve device is 10–11 mm and 12 mm in height, 
respectively, and, together with the radial force of the device, 
functions to create a seal against the native aortic valve leaflets 
and left ventricular outflow tract thereby mitigating paraval-
vular aortic regurgitation (Fig. 3).21
Potential mechanisms of aortic regurgitation include:
malpositioning of the device (too high or too low)
incomplete expansion of the device or malapposition 
against the native aortic valve leaflets or left ventricular 
outflow tract due to bulky calcifications
undersized prosthesis
aggressive pre-implant balloon aortic valvuloplasty
malcoaptation of prosthetic valve leaflets due to the guide 
wire or pigtail catheter across the valve
prolapse of native aortic valve leaflets or calcific debris 
into the prosthetic valve impeding normal leaflet excursion 
•
•
•
•
•
•
(particular to Edwards SAPIEN device)
diastolic hypotension resulting in insufficient closing 
pressure.
Corrective measures may include post-implant dilatation, 
valve-in-valve technique, and particular to the CoreValve 
device, the use of a goose-neck snare to reposition the device 
in a slightly higher position (typically 1–4 mm).22 Currently, 
there are no preprocedural screening methods to predict the 
occurrence or severity of paravalvular aortic regurgitation.
•
FIGURE 2. Percentage of new permanent pacemaker implantations after CoreValve (Medtronic, Inc) implantation (A) and after 
Edwards SAPIEN (Edwards Lifesciences) implantation (B).
FIGURE 3. Depiction of the Edwards SAPIEN (Edwards Lifes-
ciences) and CoreValve (Medtronic, Inc) device. The pericardial 
skirt, in addition to the radial force of these devices, functions 
to create a seal against the native aortic valve leaflets and left 
ventricular outflow tract to mitigate paravalvular aortic regur-
gitation.
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S T R O K E
Stroke can be a catastrophic complication even after a so-
called ‘uneventful’ TAVI procedure. Stroke has been reported 
to occur in 2.9%–6.3% of patients undergoing transfemoral 
TAVI (with both the Edwards SAPIEN or CoreValve de-
vice)12,13,15–18 and 1.8%–5% of patients undergoing transapical 
TAVI (Edwards SAPIEN).17,18,23–25 Some advocates suggest 
that the transapical approach is associated with lower stroke 
rates than the transfemoral approach. Data from prospective, 
multicenter, adjudicated, feasibility and postmarket trials, 
however, suggest comparable stroke rates between the two 
vascular approaches. The SOURCE registry, for example, 
reported a stroke rate of 2.4% and 2.6% for the transfemoral 
(n=463) and transapical approach (n=575), respectively. 
Similar stroke rates were reported for the PARTNER EU trial 
(3.2% transfemoral [n=61] vs. 2.9% transapical [n=69]).
More recently, attention has focused toward the potential 
merits of using embolic protection devices. These devices 
are intended to divert embolic clots or debris away from the 
major neck vessels and towards the descending aorta. Clinical 
studies using the Aortic Embolic Protection Device (AEPD) 
(SMT Research and Development, Ltd., Herzliya, Israel) 
(Fig. 4A) and the Embrella Embolic Deflector (Embrella 
CardiovascularTM, Inc., Malvern, PA, USA) (Fig. 4B) will 
likely initiate by Q4 of 2009. In addition to these devices, it is 
hoped that a more detailed assessment of the aorta, improved 
learning curve and less traumatic catheters will decrease the 
occurrence of stroke.
V A S C U L A R  C O M P L I C A T I O N S
Given the large-bore catheters used for TAVI procedures, 
vascular complications are of particular concern. Imaging 
techniques such as fluoroscopic angiography, computed tomo-
graphic angiography and magnetic resonance angiography can 
provide objective information of the peripheral arterial system 
– salient features include vessel diameter, degree of calcifica-
tion and atherosclerosis, obstruction, tortuousity and ulcera-
tion. The 18F CoreValve Safety and Efficacy trial reported 
a vascular complication rate of 12% whereas the Edwards 
PARTNER EU trial (22F and 24F device) reported a rate of 
27%.15,18,26 Previous analyses have demonstrated that vascular 
complications are associated with increased in-hospital mor-
tality (36% with vs. 10.3% without vascular complications) 
(Leon, M. Is TAVI the standard of care in high risk patients: 
Summary of the world-wide experience. Agioplasty Summit, 
2009. TCT Asia Pacific, April 22-24, 2009, Seoul, Korea). 
Cautious pre-procedural screening (e.g. excluding patients 
with circumferential calcification of ilio-femoral vessels) is 
essential to reduce these complications. Edwards LifeScience 
has recently introduced the 18F Edwards SAPIEN XT device 
(associated with a cobalt–chromium alloy-stented valve and 
RetroFlex 4 delivery catheter) with the expectation that it will 
reduce vascular complications.
S T A N D A R D I S A T I O N  O F  T H E  D E F I N I T I O N 
O F  C L I N I C A L  E N D P O I N T S
One complicating factor when trying to analyze and com-
pare available TAVI data stems from the great heterogeneity 
involving the definition of clinical endpoints.27–29 A number of 
organized societies have alluded to the need for standardized 
reporting practices.30–32 Furthermore, any valid treatment 
comparisons between TAVI and surgical aortic valve replace-
ment will require some common ground for clinical endpoint 
reporting. Thus, this endeavour should involve the mixed 
perspectives of interventional cardiologists, cardiac surgeons, 
clinical valve specialists, manufacturers and regulatory bod-
ies located on both sides of the Atlantic. This framework was 
successfully adopted by the Academic Research Consortium 
(ARC) to standardize the definitions of clinical endpoints for 
stent trials.33 Along these lines, the cardiology and cardiac sur-
gery communities are working towards a Valvular Academic 
Research Consortium (VARC).28
T H E  F U T U R E
The future and widespread adoption of TAVI will rely on a 
number of inter-related factors, including long-term durability 
and safety data, randomized controlled trials comparing TAVI 
with surgical aortic valve replacement and reimbursement for 
the technology.
Given the obvious requirement for long-term follow-up 
data, the number of patients with ≥3 years clinical follow-up 
is severely limited.34 It is unlikely, given the age and multiple 
FIGURE 4. Embolic protection devices. (A) The Aortic Embolic 
Protection Device (AEPD) from SMT Ltd. This device is cur-
rently available in 8F and is inserted via the transfemoral arte-
rial route. The device spans the three major neck vessels. (B) The 
Embrella Embolic Deflector Device from Embrella Cardiovascu-
lar Inc. This device is currently available in 6F and is inserted via 
the right radial artery. The device spans two major neck vessels, 
namely the braciocephalic artery and the left carotid artery.
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comorbidities of patients currently undergoing TAVI, that 
robust long-term follow-up data (i.e. >10 years) will be-
come available. Furthermore, the long-term effects of either 
crimping the valve into a delivery catheter, performing a 
post-implant balloon dilatation or valve-in-valve procedure 
are unknown currently.
Undoubtedly, randomized controlled trials will be needed 
to establish the noninferiority or superiority of TAVI (versus 
surgical aortic valve replacement) and its eventual acceptance 
into medical practice as evidence-based medicine. At this time, 
a legitimate question may follow: “Has TAVI reached an ap-
propriate level of maturity to be subjected to a randomized, 
controlled clinical trial?” The pivotal randomized PARTNER 
US trial may shed light onto this important question – enrol-
ment should be complete by the fourth quarter of 2009 with 
the primary endpoint being all-cause mortality at 1-year.
As a result of its novelty, lack of comparative data (to surgi-
cal aortic valve replacement) and a lack of cost-effectiveness 
data, reimbursement policy makers may be skeptical about the 
potential merits of TAVI. The road to reimbursement can be 
summarized in the following points:
CE mark approval is required from governmental regula-
tory bodies.
Evidence-based medicine must prove the efficacy and 
safety of the technology.
The risk/benefit ratio must be in favour of the individual 
patient.
The cost-effectiveness must be established on a societal 
level.
Owing to limited financial resources, many TAVI programs 
across Europe and Canada are restricted in the number of 
TAVI procedures they can perform. Despite these restraints, 
it is notable that approximately 8000 TAVI procedures have 
been performed since CE mark approval was obtained for 
the CoreValve (April 2007) and Edwards SAPIEN devices 
(June 2007).
In 2007, TAVI actually represented approximately 1.2% 
of all aortic valve procedures in Europe (including surgical 
aortic valve replacement); this percentage increased to 6.5% in 
2008 (Fig. 5). With an expectation of ~9000 TAVI procedures 
to be performed in 2009, TAVI may represent nearly 13% of 
all aortic valve procedures (Fig. 1). It is unquestionable that 
refinements in the technique and technology (lower profile 
devices, ability to reposition and retrieve) will provide those 
patients with aortic valve disease with new hopes and aspira-
tion in the future to come.
R E F E R E N C E S
 1. Millenium Research Group. Heart Valve Market. Toronto, On-
tario; 2008.
 2. Serruys P.W. Keynote Address – EuroPCR 2008, Barcelona, 
May 14th, 2008 Transcatheter aortic valve implantation: state 
of the art. Eurointervention 2009;4:585-565.
 3. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, 
Salamon R. European system for cardiac operative risk evalua-
tion (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9-13.
 4. O’Brien SM, Shahian DM, Filardo G, et al. The Society of Tho-
racic Surgeons 2008 Cardiac Surgery Risk Models: Part 2—Iso-
lated Valve Surgery. Ann Thorac Surg 2009; 88:S23-42.
 5. Hannan EL, Racz MJ, Jones RH, et al. Predictors of mortal-
ity for patients undergoing cardiac valve replacements in New 
York State. Ann Thorac Surg 2000;70:1212-1218.
 6. Nowicki ER, Birkmeyer NJ, Weintraub RW, et al. Multivari-
able prediction of in-hospital mortality associated with aortic 
and mitral valve surgery in Northern New England. Ann Thorac 
Surg 2004;77:1966-1977.
 7. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development 
and validation of a prognostic index for 4-year mortality in older 
adults. JAMA 2006;295:801-808.
 8. van Gameren M, Piazza N, Bogers AJJC, Takkenberg JJM, Kap-
petein A. How to assess the risk of valve surgery: quality, imple-
mentation and future risk models. Heart 2009;95:1958-1963.
•
•
•
•
FIGURE 5. This figure demonstrates that the number of surgi-
cal aortic valve replacement (SAVR) procedures continues to 
increase. Also, since CE mark approval, the percentage of total 
heart valve procedures represented by TAVI increased consid-
erably from 2007 to 2008. A similar trend is expected for 2009. 
Numbers for SAVR were obtained from Millenium Research 
Group, Ontario, Canada, European Heart Valve Market Re-
port 2008.
TRANSCATHETER AORTIC VALVE IMPLANTATION
69
 9. Piazza N, Onuma Y, Jesserun E, et al. Early and persistent in-
traventricular conduction abnormalities and requirements for 
pacemaking after after percutaneous replacement of the aortic 
valve. J Am Coll Cardiol Intv 2008;1:310-316.
 10. Calvi V, Puzzangara E, Pruiti GP, et al. Early conduction dis-
orders following percutaneous aortic valve replacement. Pacing 
Clin Electrophysiol 2009; 32(Suppl 1):S126-130.
 11. Sinhal A AL, Pasupati S, Humphries KH, et al. Atrioventricular 
block after transcatheter balloon expandable aortic valve im-
plantation J Am Coll Cardiol Intv 2008;1:305-309.
 12. Bleiziffer S, Ruge H, Mazzitelli D, et al. Results of percutane-
ous and transapical transcatheter aortic valve implantation per-
formed by a surgical team. Eur J Cardiothorac Surg 2009;35:615-
620; discussion 620-611.
 13. Grube E, Buellesfeld L, Mueller R, et al. Progress and Current 
Status of Percutaneous Aortic Valve Replacement: Results of 
Three Device Generations of the CoreValve Revalving System. 
Circ Cardiovasc Intervent 2008;1:167-175.
 14. Jilaihawi H, Chin D, Vasa-Nicotera M, et al. Predictors for 
permanent pacemaker requirement after transcatheter aortic 
valve implantation with the CoreValve bioprosthesis. Am Heart 
J 2009;157:860-866.
 15. Buellesfeld L. 1 year results from the CoreValve 18F safety and 
efficacy study. EuroPCR 2009; Barcelona.
 16. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic 
valve implantation: impact on clinical and valve-related out-
comes. Circulation 2009;119:3009-3016.
 17. Thomas M, on behalf of the SOURCE registryinvestigators. 
Thirty-day results of the SOURCE Registry - A European reg-
istry of transcatheter aortic valve implantation uisng the Ed-
wards SAPIEN valve. EuroPCR 2009; Barcellona.
 18. Schδchinger V, on the behalf of the the PARTNER EU inves-
tigators. Results from the PARTNER EU Trial: Prospective 
multicentric European registry of transcatheter aortic valve 
implantation - Primary Endpoint Analysis. EuroPCR 2009; Bar-
celona.
 19. REVIVAL II Investigators. Results from the REVIVAL II 
Study. STS 45th Annual Meeting, San Francisco, California, USA 
2009.
 20. Schuler G, on behalf of the EER participants. Post CE mark 
results from the Expanded Evaluation Registry with the 18F 
CoreValve ReValving System. Joint International Meeting 2009; 
Rome, Italy.
 21. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, 
Anderson RH. Anatomy of the aortic valvar complex and its 
implications for transcatheter implantation of the aortic valve. 
Circ Cardiovasc Intervent 2008;1:74-81.
 22. Piazza N, Schultz C, de Jaegere PP, Serruys PW. Implanta-
tion of two self-expanding aortic bioprosthetic valves during 
the same procedure-Insights into valve-in-valve implantation 
(“Russian doll concept”). Catheter Cardiovasc Interv 2008.
 23. Walther T, Simon P, Dewey T, et al. Transapical minimally in-
vasive aortic valve implantation: multicenter experience. Circu-
lation 2007;116(11 Suppl):I240-245.
 24. Svensson LG, Dewey T, Kapadia S, et al. United States feasibil-
ity study of transcatheter insertion of a stented aortic valve by 
the left ventricular apex. Annals Thoracic Surg 2008;86:46-54; 
discussion 54-45.
 25. TRAVERCE investigators. One-year follow-up results from the 
transapical TRAVERCE registry using the Edwards SAPIEN 
prosthetic heart valve. STS 45th Annual Meeting, San Francisco, 
California, USA 2009.
 26. Serruys PW. Transcatheter Aortic Valve Implantation - A Com-
prehensive Update. Nordic-Baltic Society of Cardiology Congress 
2009; June 3-5th, 2009.
 27. Thomas M, Wendler O. Transcatheter aortic valve implantation 
(TAVI): how to interpret the data and what data is required? 
Eurointervention 2009;5:25-27.
 28. Piazza N, Cutlip D, Onuma Y, Kappetein AP, de Jaegere P, 
Serruys PW. Clinical endpoints in transcatheter aortic valve 
implantation: a call to ARC for standardized definitions. Eu-
rointervention 2009;5:29-31.
 29. Piazza N, Onuma Y, de Jaegere P, Serruys PW. Guidelines for 
reporting mortality and morbidity after cardiac valve interven-
tions--need for a reappraisal? Ann Thorac Surg 2009;87:357-
358; discussion 359-360.
 30. Vahanian A, Alfieri O, Al-Attar N, et al. Transcatheter valve 
implantation for patients with aortic stenosis: a position state-
ment from the European association of cardio-thoracic surgery 
(EACTS) and the European Society of Cardiology (ESC), in 
collaboration with the European Association of Percutane-
ous Cardiovascular Interventions (EAPCI). EuroIntervention 
2008;4:193-199.
 31. Rosengart TK, Feldman T, Borger MA, et al. Percutaneous and 
minimally invasive valve procedures: a scientific statement from 
the American Heart Association Council on Cardiovascular 
Surgery and Anesthesia, Council on Clinical Cardiology, Func-
tional Genomics and Translational Biology Interdisciplinary 
Working Group, and Quality of Care and Outcomes Research 
Interdisciplinary Working Group. Circulation 2008;117:1750-
1767.
 32. Akins CW, Miller DC, Turina MI, et al. Guidelines for report-
ing mortality and morbidity after cardiac valve interventions. 
Ann Thorac Surg 2008;85:1490-1495.
 33. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in 
coronary stent trials: a case for standardized definitions. Circu-
lation 2007;115:2344-2351.
 34. Ruiz CE, Laborde JC, Condado JF, Chiam PT, Condado JA. 
First percutaneous transcatheter aortic valve-in-valve im-
plant with three year follow-up. Catheter Cardiovasc Interv 
2008;72:143-148.
